Latest Headlines

1. Biocept Announces Agreement With Aegea Biotechnologies To Develop New, Highly Sensitive PCR-Based COVID-19 Assay Utilizing Patented Switch-Blocker PCR Technology 8/6/2020

   Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc., an innovative private life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies, announce a development agreement focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus

2. Fujirebio Diagnostics Announces Initiation Of Clinical Testing For The Fully Automated Lumipulse SARS CoV-2 Antigen Assay 8/5/2020

   Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration

3. Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance With Standard Of Care Tissue-Based RAS Testing 8/5/2020

   Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care tissue-based RAS testing in the United Kingdom (UK)

4. Sterile Deep Well Plates 8/5/2020

   Porvair Sciences offers an extensive range of sterile deep well microplates for sensitive biological and drug discovery applications

5. Eurofins Technologies Launches Reagents For Automated Extraction Of Genomic SARS-CoV-2 RNA From Clinical Swab Samples 8/4/2020

   Eurofins Technologies announces the launch of reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human respiratory specimens

6. Precipio Launches Covid-19 Antibody Test In Its CLIA Laboratory 8/4/2020

   Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory, and has launched the test commercially to its pathology customer base (phase 1)

7. Personalis, Inc. Launches NeXT Liquid Biopsy, A High-Performance, Exome-Wide Liquid Biopsy Platform 8/3/2020

   Personalis, Inc., a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients

8. Quest Diagnostics Completes Acquisition Of Mid America Clinical Laboratories, Now Provides Professional Lab Management For Nearly 30 Hospitals Of Community Health Network And Ascension St. Vincent In Indiana 8/3/2020

   Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of its joint venture partners' interests in Mid America Clinical Laboratories ("MACL")

9. Sysmex America Releases Caresphere™ Workflow Solution (WS) Designed To Deliver Efficiency Increases To Labs 8/3/2020

   Sysmex America, Inc., a leading diagnostic company offering hematology, urinalysis, information systems and flow cytometry testing solutions for optimal clinical laboratory performance, announced the availability of its new clinical software application, Caresphere™ Workflow Solution (WS)

10. Microbiologics Expands Viral Capabilities For SARS-CoV-2 With New BSL-3 Laboratory At Its San Diego Facility 8/3/2020

    Microbiologics announced today that it has recently completed renovations of the virology services laboratory in its San Diego location. With completion of the renovation, Microbiologics has expanded its custom virology solutions to include Biosafety Level 3 (BSL-3) antiviral services